In a major breakthrough development, DABUR India Limited, one of India’s leading Ayurvedic companies, has completed a large scale, multi centric, clinical study on their premium Ayurvedic healthcare product– DABUR Chyawanprash. This clinical study evaluated the beneficial role of Dabur Chyawanprash as a prophylaxis remedy for COVID-19 infection. This study was conducted following applicable GCP guidelines, was approved by multiple Institutional Ethics Committees and was registered with Clinical Trials Registry of India which is a portal of ICMR.Subjects were enrolled in the study after taking an informed consent from all the study participants.
The findings of the study reveal that regular use of Dabur Chyawanprash reduced the risk of COVID-19 infection by up to 12 times in comparison to control group which was not consuming Chyawanprash. It was also noted that with regular usage of Dabur Chyawanprash, there was up to 6 times lesser severity of COVID 19 infections when compared to subjects in control group. The severity of COVID-19 was assessed as per ordinal scale published by the WHO (World Health Organization) for COVID-19.
Commenting on the revelations, Mr. Prashant Agarwal, Marketing Head - Health Supplements, Dabur India Ltd said: “In the era of COVID-19, strong immunity has become the primary need of every individual more than ever before. Dabur Chyawanprash, with the power of more than 40 Ayurvedic herbs like Amla, Ashwagandha, Giloy etc., has always stood for boosting immunity to fight illnesses. Now, with the findings of current clinical study which was conducted following GCP and ICMR ethical guidelines coming in, we are confident of helping the nation in this steep battle against COVID-19.”
“Dabur has been relentlessly pursuing the cause of providing Ayurveda based solutions backed by modern science. Dabur Chyawanprash has earlier been studied scientifically in various studies for its beneficial role on boosting immunity. The beneficial effects of this study probably are due to the proven effects of Chyawanprash on immunity. The investigational team for this current study included Doctors and Scientists from both Ayurveda as well as modern system of medicine. Dabur has submitted the results of the study to the concerned ethics committees as well as to the Ministry of AYUSH, Dabur India Ltd.’s Head - Scientific Affairs, Dr. Arun Gupta said.”
This open-label, randomized, controlled, multi centric clinical study was conducted on healthy volunteers across five different Ayurveda Institutions including Jaipur, Mumbai, Pune and two sites at Vadodara. In one group, the subject consumed one tea spoonful of Dabur Chyawanprash two times a day for a period of 3 months. A total of 696 subjects completed the study, out of which 351 subjects were in Chyawanprash group and 345 subjects were in control group that did not take Chyawanprash. This clinical study revealed Dabur Chyawanprash to be a good prophylaxis remedy for healthy individuals for its beneficial effects in the prevention of COVID-19 infection.
About Dabur India Ltd:
Dabur India Ltd is one of India’s leading FMCG Companies. Building on a legacy of quality and experience for 136 years, Dabur is today India’s most trusted name and the world’s largest Ayurvedic and Natural Health Care Company. Dabur India's FMCG portfolio nine Power Brands with distinct brand identities – Dabur Chyawanprash, Dabur Honey, Dabur Lal Tail, Dabur Honitus, Dabur Pudin Hara, Dabur Red Paste, Dabur Amla Hair Oil, Vatika and Réal fruit juice.
No comments:
Post a Comment